Maxim Group Begins Coverage on Polaryx Therapeutics (NASDAQ:PLYX)

Stock analysts at Maxim Group assumed coverage on shares of Polaryx Therapeutics (NASDAQ:PLYX) in a report issued on Friday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s target price indicates a potential upside of 227.87% from the company’s current price.

Polaryx Therapeutics Trading Down 4.4%

NASDAQ:PLYX opened at $3.05 on Friday. Polaryx Therapeutics has a 52 week low of $2.20 and a 52 week high of $48.91.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.